Buscar
TScan Therapeutics Inc
TCRXAñadir a la lista de seguimiento
0.743USD
-0.013-1.68%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
42.28MCap. mercado
PérdidaP/E TTM
Más Datos de TScan Therapeutics Inc Compañía
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Información de TScan Therapeutics Inc
Símbolo de cotizaciónTCRX
Nombre de la empresaTScan Therapeutics Inc
Fecha de salida a bolsaJul 16, 2021
Director ejecutivoMacbeath (Gavin)
Número de empleados194
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
Dirección830 Winter Street
CiudadWALTHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02451
Teléfono18573999500
Sitio Webhttps://www.tscan.com
Símbolo de cotizaciónTCRX
Fecha de salida a bolsaJul 16, 2021
Director ejecutivoMacbeath (Gavin)
Ejecutivos de TScan Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+94.43%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+94.43%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de TScan Therapeutics Inc?
Los cinco principales accionistas de TScan Therapeutics Inc son: Dr. Zoran Zdraveski, J.D., Ph.D.
¿Cuántas instituciones poseen acciones de TScan Therapeutics Inc (TCRX)?
A fecha de 2026Q1, 209 instituciones poseen acciones de TScan Therapeutics Inc, con un valor de mercado combinado de aproximadamente 36.25M, lo que representa el 59.35% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -16802335.00.